Search Results - "Arnedos, M"

Efficacy of PI3K inhibitors in advanced breast cancer by Verret, B, Cortes, J, Bachelot, T, Andre, F, Arnedos, M

“…The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway has always been a focus of interest in breast cancer due to its role in cell growth, cell…”
Get full text

St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients’ overtreatment and breaking the bank? by Arnedos, M., Gligorov, J.

Get full text

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer by Treilleux, I., Arnedos, M., Cropet, C., Wang, Q., Ferrero, J.-M., Abadie-Lacourtoisie, S., Levy, C., Legouffe, E., Lortholary, A., Pujade-Lauraine, E., Bourcier, A.-V., Eymard, J.-C., Spaeth, D., Bachelot, T.

“…Everolimus is an agent frequently associated with specific toxicities. Predictive markers of efficacy are needed to help define which patients could benefit…”
Get full text

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) by Arnedos, M., Nerurkar, A., Osin, P., A'Hern, R., Smith, I.E., Dowsett, M.

“…Analysis of estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) is increasingly being conducted in core needle…”
Get full text

Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial by Arnedos, M., Bayar, M.A., Cheaib, B., Scott, V., Bouakka, I., Valent, A., Adam, J., Leroux-Kozal, V., Marty, V., Rapinat, A., Mazouni, C., Sarfati, B., Bieche, I., Balleyguier, C., Gentien, D., Delaloge, S., Lacroix-Triki, M., Michiels, S., Andre, F.

“…The cyclin-dependent kinase 4 (CDK4)/6 inhibitor Palbociclib is a new standard treatment in hormone-receptor positive breast cancer patients. No predictive…”
Get full text

Platinum-based chemotherapy in triple-negative breast cancer by Sirohi, B., Arnedos, M., Popat, S., Ashley, S., Nerurkar, A., Walsh, G., Johnston, S., Smith, I.E.

“…Experimental data suggest that triple-negative (TN) breast cancer may have increased sensitivity to platinum-based chemotherapy but clinical data are limited…”
Get full text

Pharmacokinetic interaction involving fenofibrate and everolimus by Mir, O., Poinsignon, V., Arnedos, M., Delaloge, S., Paci, A.

Get full text

T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants by Messaoudene, M., Mourikis, T.P., Michels, J., Fu, Y., Bonvalet, M., Lacroix-Trikki, M., Routy, B., Fluckiger, A., Rusakiewicz, S., Roberti, M.P., Cotteret, S., Flament, C., Poirier-Colame, V., Jacquelot, N., Ghiringhelli, F., Caignard, A., Eggermont, A.M.M., Kroemer, G., Marabelle, A., Arnedos, M., Vicier, C., Dogan, S., Jaulin, F., Sammut, S -J, Cope, W., Caldas, C., Delaloge, S., McGranahan, N., André, F., Zitvogel, L.

“…Tumor-infiltrating lymphocytes (TILs) represent a prognostic factor for survival in primary breast cancer (BC). Nonetheless, neoepitope load and TILs cytolytic…”
Get full text

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer by Arnedos, M., Drury, S., Afentakis, M., A'Hern, R., Hills, M., Salter, J., Smith, I.E., Reis-Filho, J.S., Dowsett, M.

“…The purpose of this study was to identify any differences in key biomarkers associated with estrogen action between biopsies taken at diagnosis and at…”
Get full text

Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer by Smyth, L.M., Saura, C., Piha-Paul, S.A., Lu, J., Mayer, I.A., Brufksy, A.M., Spanggaard, I., Arnedos, M., Cutler, R.E., Hyman, D.M.

Get full text

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer by Weigel, M.T., Banerjee, S., Arnedos, M., Salter, J., A'Hern, R., Dowsett, M., Martin, L.A.

“…We have found that the platelet-derived growth factor receptor (PDGFR)/Abl signaling pathway is up-regulated as a determinant of the acquisition of resistance…”
Get full text

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? by Valenza, C., Trapani, D., Bidard, F.-C., Gligorov, J., Cortés, J., Turner, N., Dalenc, F., Penault-Llorca, F., Freyer, G., Arnedos, M., Villanueva, C., Loibl, S., Pistilli, B., Curigliano, G.

“…For patients with hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) metastatic breast cancer (mBC) progressed on…”
Get full text

An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy by Blaye, C., Darbo, É., Debled, M., Brouste, V., Vélasco, V., Pinard, C., Larmonier, N., Pellegrin, I., Tarricone, A., Arnedos, M., Commeny, J., Bonnefoi, H., Larmonier, C., MacGrogan, G.

“…When triple-negative breast cancer (TNBC) patients have residual disease after neoadjuvant chemotherapy (NACT), they have a high risk of metastatic relapse…”
Get full text

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort by Epaillard, N., Lusque, A., Jacot, W., Mailliez, A., Bachelot, T., Arnedos, M., Le Du, F., Brain, E., Ferrero, J.M., Massard, V., Desmoulins, I., Mouret-Reynier, M.A., Levy, C., Gonçalves, A., Leheurteur, M., Petit, T., Filleron, T., Bosquet, L., Pistilli, B., Frenel, J.S.

“…Breast cancer (BC) is the second most common cancer that metastasizes to the brain. Particularly up to half of patients with human epidermal growth factor…”
Get full text

Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy by Mathieu, M.C., Mazouni, C., Kesty, N.C., Zhang, Y., Scott, V., Passeron, J., Arnedos, M., Schnabel, C.A., Delaloge, S., Erlander, M.G., André, F.

“…The aim of neoadjuvant chemotherapy is to increase the likelihood of successful breast conservation surgery (BCS). Accurate identification of BCS candidates is…”
Get full text

Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer by Arnedos, M, Scott, V, Job, B, De La Cruz, J, Commo, F, Mathieu, M.C, Wolp-Diniz, R, Richon, C, Campone, M, Bachelot, T, Dalenc, F, Dessen, P, Lacroix, L, Lazar, V, Soria, J.C, Delaloge, S, Andre, F

“…Abstract Breast cancer includes high number of molecular entities targetable by specific agents. In this study, array CGH and PIK3CA/AKT1 mutations were used…”
Get full text

Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer by Andre, F., Conforti, R., Moeder, C.B., Mauguen, A., Arnedos, M., Berrada, N., Delaloge, S., Tomasic, G., Spielmann, M., Esteva, F.J., Rimm, D.L., Michiels, S.

“…The purpose of this study was to evaluate the prognostic and predictive value of p27 expression in patients with early breast cancer. Quantitative…”
Get full text

P08.03 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES by Brandsma, D., Dieras, V., Altintas, S., Anders, C., Arnedos, M., Gelderblom, H., Soetekouw, P., Jager, A., van Linde, M., Aftimos, P.

“…BACKGROUND: Without active delivery across the blood-brain barrier (BBB), efficacy of doxorubicin in intracranial tumors is limited. Glutathione pegylated…”
Get full text

PO-497 Microtubule regulatory proteins as predictive biomarkers of taxane-based chemoresistance in breast cancer? by Moindjie, H, Rodrigues-Ferreira, S, Dujaric, ME, Servant, N, Asselain, B, Arnedos, M, Pierga, JY, André, F, Nahmias, C

“…IntroductionNeo-adjuvant chemotherapy combining taxanes and anthracyclines represents an interesting option for a number of breast cancer patients. However,…”
Get full text

801 ORAL High Throughput Molecular Analyses to Select Patients for Targeted Agents by Arnedos, M, De La Cruz, J, Job, B, Scott, V, Dessen, P, Gentien, D, Roman-Roman, S, Delaloge, S, Lazar, V, Andre, F

Get full text